FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114496951> ?p ?o ?g. }

• W2114496951 abstract "BackgroundArtemisinin resistance in Plasmodium falciparum manifests as slow parasite clearance but this measure is also influenced by host immunity, initial parasite biomass and partner drug efficacy. This study collated data from clinical trials of artemisinin derivatives in falciparum malaria with frequent parasite counts to provide reference parasite clearance estimates stratified by location, treatment and time, to examine host factors affecting parasite clearance, and to assess the relationships between parasite clearance and risk of recrudescence during follow-up.MethodsData from 24 studies, conducted from 1996 to 2013, with frequent parasite counts were pooled. Parasite clearance half-life (PC1/2) was estimated using the WWARN Parasite Clearance Estimator. Random effects regression models accounting for study and site heterogeneity were used to explore factors affecting PC1/2 and risk of recrudescence within areas with reported delayed parasite clearance (western Cambodia, western Thailand after 2000, southern Vietnam, southern Myanmar) and in all other areas where parasite populations are artemisinin sensitive.ResultsPC1/2 was estimated in 6975 patients, 3288 of whom also had treatment outcomes evaluate d during 28–63 days follow-up, with 93 (2.8 %) PCR-confirmed recrudescences. In areas with artemisinin-sensitive parasites, the median PC1/2 following three-day artesunate treatment (4 mg/kg/day) ranged from 1.8 to 3.0 h and the proportion of patients with PC1/2 >5 h from 0 to 10 %. Artesunate doses of 4 mg/kg/day decreased PC1/2 by 8.1 % (95 % CI 3.2–12.6) compared to 2 mg/kg/day, except in populations with delayed parasite clearance. PC1/2 was longer in children and in patients with fever or anaemia at enrolment. Long PC1/2 (HR = 2.91, 95 % CI 1.95–4.34 for twofold increase, p < 0.001) and high initial parasitaemia (HR = 2.23, 95 % CI 1.44–3.45 for tenfold increase, p < 0.001) were associated independently with an increased risk of recrudescence. In western Cambodia, the region with the highest prevalence of artemisinin resistance, there was no evidence for increasing PC1/2 since 2007.ConclusionsSeveral factors affect PC1/2. As substantial heterogeneity in parasite clearance exists between locations, early detection of artemisinin resistance requires reference PC1/2 data. Studies with frequent parasite count measurements to characterize PC1/2 should be encouraged. In western Cambodia, where PC1/2 values are longest, there is no evidence for recent emergence of higher levels of artemisinin resistance." @default.
• W2114496951 created "2016-06-24" @default.
• W2114496951 creator A5002377503 @default.
• W2114496951 creator A5005365222 @default.
• W2114496951 creator A5007007103 @default.
• W2114496951 creator A5008949758 @default.
• W2114496951 creator A5010966506 @default.
• W2114496951 creator A5012663079 @default.
• W2114496951 creator A5012815299 @default.
• W2114496951 creator A5013453998 @default.
• W2114496951 creator A5014977844 @default.
• W2114496951 creator A5016235646 @default.
• W2114496951 creator A5018692963 @default.
• W2114496951 creator A5019034894 @default.
• W2114496951 creator A5019096760 @default.
• W2114496951 creator A5022330980 @default.
• W2114496951 creator A5022365212 @default.
• W2114496951 creator A5023010999 @default.
• W2114496951 creator A5024467013 @default.
• W2114496951 creator A5027270405 @default.
• W2114496951 creator A5028227666 @default.
• W2114496951 creator A5028327649 @default.
• W2114496951 creator A5030483954 @default.
• W2114496951 creator A5031555005 @default.
• W2114496951 creator A5033754121 @default.
• W2114496951 creator A5034097318 @default.
• W2114496951 creator A5044134017 @default.
• W2114496951 creator A5047204174 @default.
• W2114496951 creator A5051408897 @default.
• W2114496951 creator A5054484476 @default.
• W2114496951 creator A5056799272 @default.
• W2114496951 creator A5058225296 @default.
• W2114496951 creator A5061182167 @default.
• W2114496951 creator A5063465178 @default.
• W2114496951 creator A5065968307 @default.
• W2114496951 creator A5067034828 @default.
• W2114496951 creator A5069843611 @default.
• W2114496951 creator A5069947073 @default.
• W2114496951 creator A5071989286 @default.
• W2114496951 creator A5072638559 @default.
• W2114496951 creator A5074396287 @default.
• W2114496951 creator A5076511543 @default.
• W2114496951 creator A5078483356 @default.
• W2114496951 creator A5078711287 @default.
• W2114496951 creator A5080121371 @default.
• W2114496951 creator A5080284515 @default.
• W2114496951 creator A5081603649 @default.
• W2114496951 creator A5083740562 @default.
• W2114496951 creator A5084119337 @default.
• W2114496951 creator A5084217335 @default.
• W2114496951 creator A5088444182 @default.
• W2114496951 creator A5090639293 @default.
• W2114496951 date "2015-09-22" @default.
• W2114496951 modified "2023-10-13" @default.
• W2114496951 title "Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis" @default.
• W2114496951 cites W1975192103 @default.
• W2114496951 cites W1977247044 @default.
• W2114496951 cites W1977256372 @default.
• W2114496951 cites W1977852231 @default.
• W2114496951 cites W1990913630 @default.
• W2114496951 cites W2002469675 @default.
• W2114496951 cites W2003038055 @default.
• W2114496951 cites W2007719429 @default.
• W2114496951 cites W2020465799 @default.
• W2114496951 cites W2040095486 @default.
• W2114496951 cites W2040713555 @default.
• W2114496951 cites W2059636803 @default.
• W2114496951 cites W2076735348 @default.
• W2114496951 cites W2079580943 @default.
• W2114496951 cites W2081078606 @default.
• W2114496951 cites W2100109827 @default.
• W2114496951 cites W2100200014 @default.
• W2114496951 cites W2100350165 @default.
• W2114496951 cites W2100685288 @default.
• W2114496951 cites W2103830263 @default.
• W2114496951 cites W2109181646 @default.
• W2114496951 cites W2118868447 @default.
• W2114496951 cites W2120622726 @default.
• W2114496951 cites W2121172260 @default.
• W2114496951 cites W2124634096 @default.
• W2114496951 cites W2126930838 @default.
• W2114496951 cites W2127740142 @default.
• W2114496951 cites W2129428401 @default.
• W2114496951 cites W2132093894 @default.
• W2114496951 cites W2134089025 @default.
• W2114496951 cites W2135926190 @default.
• W2114496951 cites W2139324809 @default.
• W2114496951 cites W2139622114 @default.
• W2114496951 cites W2142025416 @default.
• W2114496951 cites W2144207524 @default.
• W2114496951 cites W2146238956 @default.
• W2114496951 cites W2148068300 @default.
• W2114496951 cites W2161311583 @default.
• W2114496951 cites W2168987526 @default.
• W2114496951 cites W2171102256 @default.
• W2114496951 cites W2320022633 @default.
• W2114496951 doi "https://doi.org/10.1186/s12936-015-0874-1" @default.
• W2114496951 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4578675" @default.
• W2114496951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26390866" @default.
• W2114496951 hasPublicationYear "2015" @default.

• next